| Prosonix and Syrris announce Marketing Partnershop for Prosonix Sonolab Laboratory Scale Equipment | 01/10/2008 |
|||
| Prosonix Ltd (Oxford, UK) and Syrris (Royston, UK) are delighted to announce a new marketing partnership which positions Syrris as the prime channel to market for Prosonix’s new SonoLab laboratory scale sonocrystallization and sonoprocessing equipment. | ||||
|
 |
 |
|
|
| Pfizer Select Prosonix Sonocrystallization Technology for Primary API Manufacture | 16/09/2008 |
|||
| Prosonix Ltd (Oxford, UK) is delighted to announce that Pfizer Global Manufacturing will implement Prosonix’ Prosonitron reactor and sonocrystallization process technology at Pfizer’s manufacturing facilities in Ireland. The Prosonitron technology will be used in the controlled crystallization and production of a number of Pfizer products, and follows an extended period of collaboration and testing with Pfizer Global Research and Development in Sandwich (UK). The Prosonitron technology is proven across scale, facilitating the Complete Crystallization Control of many aspects of complex pharmaceutical crystallization processes, including control of crystal size, shape, and purity, the selective production of polymorphs, enhancing both manufacturing productivity and ultimate formulation performance of drug product. The technology is increasingly being recognised as an important new option in pharmaceutical API crystallization. | ||||
|
|
|
|
|
| Prosonix Appoints New Non-Executive Chairman | 06/03/2008 |
|||
| Prosonix (Oxford, UK) leaders in the commercialization of proprietary ultrasonic particle engineering technologies and added value ultrasonic process chemistry solutions for the pharmaceutical and related industries, are delighted to announce the appointment of Dr Jim Phillips to the key post of Non-Executive Chairman. | ||||
|
|
|
|
|
| Prosonix concludes worldwide exclusive license for Novel Ultrasonic Particle Engineering Process | 28/01/2008 |
|||
| Prosonix Ltd (Oxford, UK), and Rafael (Haifa, Israel), are pleased announce the conclusion of a worldwide exclusive license for the exploitation of the novel Rafael ultrasonic particle engineering process technology in the pharmaceutical and fine chemical markets. The license deal is the culmination of almost 18 months of collaboration and discussion between Prosonix and Rafael, and follows successful demonstration and enhancement of the Rafael process technology on a range of active pharmaceutical ingredients and key excipients using Prosonix proprietary ProsonitronTM ultrasonic reactors. Importantly the Rafael process patent is already granted in key geographies and has wide ranging utility independent of the method of ultrasound delivery in secondary particle engineering, post initial crystallization and isolation. Key applications include particle rounding to improve product flowability and rheology, compressibility, and added concomitant benefits in formulation performance and assurance. Additional opportunities in taste masking, coating, and granulation are also emerging. Used in combination, the Rafael process technology and the proven Prosonix ProsonitronTM process and reactor technology represents an ideal solution to a range of common secondary pharmaceutical manufacturing problems, and overcomes many of the problems hitherto associated with classical dry milling or micronisation | ||||
|
|
|
|
|
| Prosonix Ltd Completes £5M Funding Round | 30/11/2007 |
|||
| Prosonix Ltd (Oxford, UK), acknowledged leaders in the commercialization of proprietary ultrasonic particle engineering technologies and added value ultrasonic process chemistry solutions for the pharmaceutical and related industries, have today successfully completed a £5 million total funding round designed to underpin and drive the accelerated future growth plans of the business. | ||||
|
|
|
|
|
| New SonoLab Development Suite Launched | 27/09/2007 |
|||
| Prosonix Launch New SonoLabTM Laboratory Scale Sonocrystallization Development Suite at CPHI Worldwide 2007 As part of the drive to make commercially viable sonocrystallization solutions easily accessible to the research and development activities, Prosonix [Oxford, UK] have launched a suite of manual, semi-automated, and fully automated sonocrystallization equipment. Sonocrystallization technology allows chemists to control particle size, morphology and polymorphs. This results in higher quality crystalline materials with improved physicochemical properties and formulation performance. Designed for use in our clients own laboratories, these span the full pharmaceutical life cycle from Discovery to Market. The value of the systems is further enhanced when used in conjunction with the unique Tutorial Manual and Training options that are available with each system. The three new systems are: SonoLab™ Discovery - A system ideal for parallel screening activities. SonoLab Discovery introduces development chemists to hands on sonocrystallization and will speed up the evaluation of new compounds at a 50ml scale. SonoLab™ Research - A system with added sophistication perfect for process research. Whether it is small batches, continuous or continuous with recirculation, this equipment has the flexibility to deliver batches of up to 2 litres. SonoLab™ Development - Using a larger reactor, this moves development capabilities forward such that it can be used in conjunction with pilot scale 10 - 20 litre reactors. Together, the SonoLab™ suite provides a very powerful tool for real time in-situ control of nucleation and by manipulation gives the ultimate ground up tailored particle engineering solution. All three systems are based on Prosonix's successful pharmaceutical industrialisation of sonocrystallization and can be linked to on-line analytical techniques such as Raman, FBRM, and turbidity. David Hipkiss, Prosonix CEO commented “The launch of the new SonoLabTM suite is a natural extension of the provision of our unique sonocrystallization solutions which are increasingly being used across scale by the worldwide pharmaceutical industry. Using any of the systems enables a seamless transition into the already proven Prosonitron™ range of commercial scale sonoprocessing reactors. This gives a high degree of assurance that positive results can be readily replicated at commercial scale.” | ||||
|
|
|
|
|